Eli Lilly's Taltz (ixekizumab) has been approved in the US for moderate-to-severe plaque psoriasis, along with Teva's asthma drug Cinqair (reslizumab). The US Food and Drug Administration today ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Teva Pharmaceuticals’ TEV-479 (olanzapine ... in 2009. It is marketed by Eli Lilly as Zyprexa and a longer-acting version ...

They include a 3% WAC price increase implemented for Eli Lilly’s (NYSE ... such as AbbVie (ABBV), GSK (GSK), and Teva (TEVA), was subject to an FTC warning related to patent violations over ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly is to buy the private biotech Disarm Therapeutics ... NICE has already recommended Teva’s rival Ajovy (fremanezumab) this year, although it has rejected Novartis’ Aimovig (erenumab ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.